Geneva, Aug. 17 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129670) titled 'A single-arm study on the efficacy and safety of SOX plus tislelizumab as neoadjuvant therapy for locally advanced gastric cancer' on Aug. 7.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Army Medical University
Condition:
Locally advanced gastric cancer
Intervention:
Intervention group:his study is a full-course neoadjuvant therapy clinical trial, which adopts a multi-drug chemotherapy and immunotherapy regimen combining the SOX regimen with tislelizumab. All patients will receive six cycles of neoadjuvant therapy before the operation, followed...